Moolec Science (MLEC) versus Its Competitors Critical Review

Moolec Science (NASDAQ:MLEC) is one of 668 public companies in the “Holding & other investment offices” industry, but how does it contrast to its rivals? We will compare Moolec Science to related companies based on the strength of its analyst recommendations, valuation, risk, profitability, earnings, dividends and institutional ownership.

Earnings and Valuation

This table compares Moolec Science and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Moolec Science	$5.63 million	-$7.31 million	-4.25
Moolec Science Competitors	$968.52 million	$78.18 million	60.40

Moolec Science’s rivals have higher revenue and earnings than Moolec Science. Moolec Science is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

0.1% of Moolec Science shares are held by institutional investors. Comparatively, 54.2% of shares of all “Holding & other investment offices” companies are held by institutional investors. 19.9% of Moolec Science shares are held by insiders. Comparatively, 26.4% of shares of all “Holding & other investment offices” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Moolec Science and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Moolec Science	-129.97%	-93.88%	-33.37%
Moolec Science Competitors	-17.70%	-42.87%	-0.63%

Analyst Ratings

This is a breakdown of recent ratings for Moolec Science and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Moolec Science	0	0	1	0	3.00
Moolec Science Competitors	128	730	960	19	2.47

Moolec Science currently has a consensus target price of $6.00, suggesting a potential upside of 606.30%. As a group, “Holding & other investment offices” companies have a potential upside of 54.27%. Given Moolec Science’s stronger consensus rating and higher possible upside, analysts plainly believe Moolec Science is more favorable than its rivals.

Volatility and Risk

Moolec Science has a beta of -0.54, indicating that its stock price is 154% less volatile than the S&P 500. Comparatively, Moolec Science’s rivals have a beta of 0.03, indicating that their average stock price is 97% less volatile than the S&P 500.

Summary

Moolec Science rivals beat Moolec Science on 10 of the 13 factors compared.

About Moolec Science

Moolec Science SA, a science-based food ingredient company, focuses on developing real animal proteins in plants using molecular farming. It offers Chymosin SPC, a dairy ingredient; GLA SONOVA, a nutritional oil; POORK+, a plant-based, animal meat free ingredient with porcine proteins in soybeans; and BEEF+, a meat replacement product. It operates in the United States, Europe, and South America. The company was founded in 2020 and is based in Luxembourg.